E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
hormone refractory prostate carcinoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10036908 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
PHASE I to assess the tolerability of weekly docetaxel combined with daily oral low doses of prednisone and cyclophosphamide in patients with hormone-refractory prostate carcinoma PHASE II to evaluate the activity of such combination regarding the Overall Response Rate |
|
E.2.2 | Secondary objectives of the trial |
to evaluate the activity of such combination with regard to PSA Biochemical Response Rate BRR, 50 decrease of PSA value , Time to Progression TTP , Time to Biochemical Progression TTPB to assess, through retrospective analysis, the possibility of predicting response to metronomic chemotherapy by basal dosing and subsequent monitoring of circulating levels of VEGF and CEC, in order to identify early markers of response to this approach. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Histologically confirmed prostate adenocarcinoma foci of neuroendocrine differentiation are permitted Metastatic disease with documented clinical progression CT or bone scan, MRI and/or biochemical progression PSA increase refractory to hormone therapy. For those patients whose the sole evidence of progressione is the PSA raise, a minimum value of 20 ng/ml of PSA is requested for accrual Measurable disease one-dimension and/or non-measurable e.g. new lesions on bone scan . In case of sole clinical progression, patients must have at least one measurable lesione according to RECIST criteria Patients must have received a previous hormonal therapy defined as follows surgical castration or medical castration LHRH agonists with or without anti-androgens if the patient has been treated with LHRH analogues, these must be continued Evaluation of anti-androgen withdrawal syndrome if the patients has been treated with anti-androgens, these must have been withdrawn since 4 weeks, in case of flutamide or cyproterone acetate, or 6 weeks in case of bicalutamide; patients must show further progression, though the antiandrogen withdrawal, before entering the study Suppressed levels of testosterone T 8804; 50 ng/dl . Previous oral estramustine is permitted; however, this drug must have been withdrawn from at least 4 weeks, with complete recovery from its side-effects Previous radiotherapy is permitted, if completed from at least 4 weeks and covering 25 of bone marrow, with with complete recovery from its side-effects Previous surgery is permitted, even with palliative intent, if performed from at least 4 Life expectancy 3 months Age 18 and 80 years PS 8804; 2 ECOG Scale Neutrophils 8805; 1.500/L; Platelets 8805; 100.000/L; Hemoglobin 8805; 9 g/dl AST e ALT 8804;2.5 times upper normal limit; Bilirubin 8804;1.5 times upper normal limit; Creatinine 8804;1.5 times upper normal limit for creatinine values between 1.4 e 1.5 times, creatinine clearance will be calculated, and the clearance will have to be 8805;50ml/min Accessibility to therapy and follow up for patients Written informed consent |
|
E.4 | Principal exclusion criteria |
Central nervous system metastases Other tumors, except skin basalioma unless the patient is free of disease from 8805;5 years Severe respiratory or cardiovascular diseases congestive heart failure, positive history for acure myocardial infarction, angina pectoris, in the 6 moths preceding the study enter; non-controlled arrhythmias or hypertension Non-controlled diabetes mellitus , peptic ulcer, other contraindications to the use of corticosteroids Active infections Severe peripheral neuropathy 8805; grade 2 NCI-CTC . Severe neurological or psychiatric impairments Previous chemotherapy except estramustine, if withdrawn from at least 4 weeks before entering the study Concomitant treatment with other antineplastic drugs except LHRH analogue Accrual in other clinical trials with other experimental drugs in the 30 days preceding the inclusion in the study, or concomitant therapy with other experimental drugs Previous therapy with radioisotopes e.g strontium or samarium ; Systemic corticosteroid therapy for reason different from those specified in the protocol Hypersensitivity to Polysorbate 80 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 0 |